Crossmark

NRI and SIRI are the optimal combinations for prognostic risk stratification in patients with non-small cell lung cancer after EGFR-TKI therapy

Published Online: 2024-09-20

Authors

Liu, Xia

Wang, Peipei https://orcid.org/0000-0001-7201-4928
Liu, Guolong
License Information

Text and Data Mining valid from 2024-09-20

Version of Record valid from 2024-09-20
More Information

Article History

Received: 1 August 2024

Accepted: 11 September 2024

First Online: 20 September 2024

Declarations

:

: All the authors declare that there is no conflict of interest regarding the publication of this paper.

: This study was approved by the Ethics Committee of Guangzhou First People's Hospital (No. K-2024-108-01). All participants were provided with written informed consent.

Document is current